ASTRA Therapeutics

ASTRA Therapeutics is a Swiss-American biotechnology company specializing in the design of precision anti-parasitic drugs (parasiticides) for animal health, human medicine, and agriculture. Utilizing its proprietary ParaX platform, the company exploits structural differences between parasite and host tubulin to develop highly selective small molecules called Parabulins. These agents are designed to disrupt parasite cell division while sparing host cells, addressing the critical global challenge of drug resistance in parasitic diseases. ASTRA's pipeline includes candidates for major indications such as heartworm in companion animals and coccidiosis in livestock. The company is a spin-off from the Paul Scherrer Institute and is backed by leading venture capital firms.